Global Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Forecast 2024-2030- Product Image

Sale

Global Anti-obesity Prescription Drugs Market by Drug Class (Bupropion & Naltrexone, Liraglutide, Lorcaserin), Age Group (Adult, Pediatric), Distribution Channel - Forecast 2024-2030

Report
189 Pages
March 2024
Region: Global
360iResearch™
ID: 4904662

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Anti-obesity Prescription Drugs Market size was estimated at USD 6.22 billion in 2023, USD 6.71 billion in 2024, and is expected to grow at a CAGR of 8.12% to reach USD 10.74 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Anti-obesity Prescription Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-obesity Prescription Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Anti-obesity Prescription Drugs Market, highlighting leading vendors and their innovative profiles. These include Alisier Drugs Pvt. Ltd., Arena Pharmaceuticals Ltd, Arrowhead Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Currax Pharmaceuticals LLC, Eisai Co., Ltd, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Norgine BV, Novo Nordisk A/s, SHIONOGI & Co., Ltd., Takeda Pharmaceutical Company Limited, VIVUS LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Anti-obesity Prescription Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Bupropion & Naltrexone
- Liraglutide
- Lorcaserin
- Orlistat
- Phentermine & Topiramate
Age Group
- Adult
- Pediatric
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Anti-obesity Prescription Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-obesity Prescription Drugs Market?
What are the technology trends and regulatory frameworks in the Anti-obesity Prescription Drugs Market?
What is the market share of the leading vendors in the Anti-obesity Prescription Drugs Market?
Which modes and strategic moves are suitable for entering the Anti-obesity Prescription Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Anti-obesity Prescription Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of obesity and related chronic diseases
5.1.1.2. Growing unhealthy and sedentary lifestyle
5.1.1.3. Advancement in medical research by drug-manufacturing companies, medical universities and institutes, and government agencies
5.1.2. Restraints
5.1.2.1. Side effect related to anti-obesity drugs
5.1.3. Opportunities
5.1.3.1. Introduction of novel anti-obesity drugs
5.1.3.2. Accelerating awareness towards obesity management
5.1.4. Challenges
5.1.4.1. Availability of alternative treatment options
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Anti-obesity Prescription Drugs Market, by Drug Class

6.1. Introduction
6.2. Bupropion & Naltrexone
6.3. Liraglutide
6.4. Lorcaserin
6.5. Orlistat
6.6. Phentermine & Topiramate

7. Anti-obesity Prescription Drugs Market, by Age Group

7.1. Introduction
7.2. Adult
7.3. Pediatric

8. Anti-obesity Prescription Drugs Market, by Distribution Channel

8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy

9. Americas Anti-obesity Prescription Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Anti-obesity Prescription Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Anti-obesity Prescription Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Alisier Drugs Pvt. Ltd.
13.1.2. Arena Pharmaceuticals Ltd
13.1.3. Arrowhead Pharmaceuticals, Inc.
13.1.4. Boehringer Ingelheim International GmbH
13.1.5. Bristol-Myers Squibb Company
13.1.6. Currax Pharmaceuticals LLC
13.1.7. Eisai Co., Ltd
13.1.8. F. Hoffmann-La Roche AG
13.1.9. GlaxoSmithKline PLC
13.1.10. Norgine BV
13.1.11. Novo Nordisk A/s
13.1.12. SHIONOGI & Co., Ltd.
13.1.13. Takeda Pharmaceutical Company Limited
13.1.14. VIVUS LLC
13.1.15. Zydus Lifesciences Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET RESEARCH PROCESS
FIGURE 2. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET DYNAMICS
FIGURE 7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
FIGURE 8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 6. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY BUPROPION & NALTREXONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY LORCASERIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PHENTERMINE & TOPIRAMATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 12. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 29. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. CANADA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 33. MEXICO ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 46. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. CHINA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. INDIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. JAPAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. THAILAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 83. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 84. DENMARK ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. EGYPT ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. FINLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. GERMANY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. ITALY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 111. NORWAY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 113. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. POLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. QATAR ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 129. SPAIN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. TURKEY ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. ANTI-OBESITY PRESCRIPTION DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 146. ANTI-OBESITY PRESCRIPTION DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. ANTI-OBESITY PRESCRIPTION DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Alisier Drugs Pvt. Ltd.
Arena Pharmaceuticals Ltd
Arrowhead Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Currax Pharmaceuticals LLC
Eisai Co., Ltd
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Norgine BV
Novo Nordisk A/s
SHIONOGI & Co., Ltd.
Takeda Pharmaceutical Company Limited
VIVUS LLC
Zydus Lifesciences Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	189
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 6.71 Billion
Forecasted Market Value ( USD ) by 2030	$ 10.74 Billion
Compound Annual Growth Rate	8.1%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,802GBP €3624EUR$3,749USD£3,113GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,549GBP €4591EUR$4,749USD£3,944GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,297GBP €5558EUR$5,749USD£4,774GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,044GBP €6525EUR$6,749USD£5,605GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7613EUR$7,874USD£6,539GBP €8458EUR$8,749USD£7,265GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Anti-obesity Prescription Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Anti-obesity Medication Market Size, Share & Trends Analysis Report by Product (Approved, Off-label), Mechanism Of Action (Peripherally Acting Drugs, Centrally Acting Drugs), Distribution Channel, Region, and Segment Forecasts, 2024-2030

Global Anti-obesity Therapeutics Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), End-use (Ambulatory Surgical Centers, Hospitals, Specialty Clinics) - Forecast 2024-2030

Growth Opportunities in Obesity Drugs and Delivery Platforms